Try our mobile app

General information

Country: UNITED STATES

Sector: Drug Manufacturers — Specialty and Generic

Categories: @cannabis-players   

CV Sciences, Inc. provides specialty pharmaceutical products. The Company focuses on manufacturing, marketing, and selling plant-based CBD products to a range of market sectors, as well as develops CBD-based novel therapeutics utilizing CBD. CV Sciences invests in the scientific evidence necessary to receive self affirmed generally recognized as safe (GRAS) status.
  • Current market environment: negative. Prices of production are 16.8% lower compared to the last 12 months (LTM)
  • Prices of production are at 11.7% percentile over the past 5 years, adjusted for inflation
  • Dividend yield for the last twelve months 0.0%
  • Free cash flow yield -46.5% (LTM), projected -127.3%
  • Share price is 48.3% higher than minimum and 96.4% lower than maximum for the last 3 years
  • The company is undervalued by EV / LTM EBITDA multiple compared to target level (-0.4x vs
    )
  • The company is undervalued by EV / projected EBITDA multiple compared to target level (
    vs
    )

Key Financials (Download financials)

Ticker: CVSI
Share price, USD:  (+7.2%)0.043
year average price 0.0455  


year start price 0.1260 2022-04-02

max close price 0.1260 2022-04-02

min close price 0.0290 2022-12-23

current price 0.0430 2023-04-01
Common stocks: 100 018 511

Dividend Yield:  0.0%
FCF Yield LTM / expected: -46.5% / -127.3%
EV / LTM EBITDA: -0.4x
Production prices change from LTM: -16.8%
EV / projected EBITDA:
Target EV / EBITDA (hist percentile):
Express share price potential:
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 4
Net Debt ($m): 1
EV (Enterprise Value): 5
EBITDA LTM ($m): -13
EV / LTM EBITDA: -0.4x
Price to Book: -8.1x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF / Free Cash Flow ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / LTM EBITDA and 75% percentile

Potential dynamics

News


2023-03-29Seeking Alpha

CV Sciences, Inc. (CVSI) Q4 2022 Earnings Call Transcript

2023-03-24PRNewsWire

CV SCIENCES, INC. TO ANNOUNCE YEAR END AND FOURTH QUARTER 2022 RESULTS ON MARCH 29, 2023

2022-11-14Seeking Alpha

CV Sciences, Inc. (CVSI) Q3 2022 Earnings Call Transcript

2022-08-15Seeking Alpha

CV Sciences, Inc. (CVSI) CEO Joseph Dowling on Q2 2022 Results - Earnings Call Transcript

2022-05-16Seeking Alpha

CV Sciences, Inc. (CVSI) CEO Joseph Dowling on Q1 2022 Results - Earnings Call Transcript

2022-03-28GlobeNewsWire

CV Sciences, Inc. to Announce Fourth Quarter and Full Year 2021 Results on March 31, 2022

2022-01-11Benzinga

CV Sciences Launches +PlusCBD Pain Relief Topicals With Products For Athletes, Arthritis Patients

2021-11-23Zacks Investment Research

Here's Why CV Sciences, Inc. (CVSI) Looks Ripe for Bottom Fishing

2021-11-15Benzinga

CV Sciences 3Q Financials Continue To Improve Cost Structure, Praises California CBD Legislation

2021-11-15Zacks Investment Research

CV Sciences, Inc. (CVSI) Reports Break-Even Earnings for Q3
More information for subscribed users:
detailed calculation of Potential,
commodities and currency affecting the company